Még nem toboroz
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633· 3. fázis· Eli Lilly and Company· Forrás
Contact: Maria Nemesio (principal investigator)
Toboroz
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
NCT07783802· 2. fázis· Eli Lilly and Company· Forrás
Contact: Marina Uhrig (principal investigator)
Toboroz
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579· 3. fázis· Eli Lilly and Company· Forrás
Contact: Marina Uhrig (principal investigator)
Toboroz
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245· 2. fázis· Eli Lilly and Company· Forrás
Contact: Pablo Doreski (principal investigator)
Toboroz
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Toboroz
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· 3. fázis· Eli Lilly and Company· Forrás
Contact: Marina Uhrig (principal investigator)
Toboroz
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· 3. fázis· Eli Lilly and Company· Forrás
Contact: Christian Fuentes (principal investigator)
Toboroz
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· 3. fázis· Eli Lilly and Company· Forrás
Contact: Marina Uhrig (principal investigator)
Toboroz
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173· 2. fázis· Eli Lilly and Company· Forrás
Contact: Pablo Doreski (principal investigator)
Toboroz
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· 3. fázis· Eli Lilly and Company· Forrás
Contact: Matias Bori (principal investigator)
Toboroz
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634· 3. fázis· Celcuity Inc· Forrás
Contact: Nadene Zack, MS
Fut, nem toboroz
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217· 2. fázis· Avalyn Pharma Inc.· Forrás
Contact: Pablo Doreski
Fut, nem toboroz
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265· 3. fázis· Immutep S.A.S.· Forrás
Fut, nem toboroz
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· 3. fázis· Pfizer· Forrás
Meghívásos bevonás
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
NCT06475742· 3. fázis· Viatris Innovation GmbH· Forrás
Fut, nem toboroz
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995· 3. fázis· Eli Lilly and Company· Forrás
Contact: Maria De Salvo (principal investigator)
Fut, nem toboroz
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401· 2. fázis· Avalyn Pharma Inc.· Forrás
Fut, nem toboroz
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535· 3. fázis· United Therapeutics· Forrás
Contact: Antonela Iannazzo
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT05851443· 2. fázis· Incyte Corporation· Forrás
Meghívásos bevonás
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· 3. fázis· Pfizer· Forrás
Toboroz
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198· 3. fázis· Eli Lilly and Company· Forrás
Contact: Maria Fernandez (principal investigator)
Fut, nem toboroz
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500· 3. fázis· Viatris Innovation GmbH· Forrás
Fut, nem toboroz
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565· 2/3. fázis· Biogen· Forrás
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT05169567· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449· 2. fázis· Pfizer· Forrás